©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 14, 2025; 31(10): 104429
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.104429
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.104429
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
Fei-Yu Zhao, Xiao-Ming Zhang, Nian-Song Qian, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100853, China
Author contributions: Zhao FY wrote the article; Zhang XM created the tables; Qian NS provided the writing ideas.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, China.
Received: December 19, 2024
Revised: January 13, 2025
Accepted: January 24, 2025
Published online: March 14, 2025
Processing time: 68 Days and 12.8 Hours
Revised: January 13, 2025
Accepted: January 24, 2025
Published online: March 14, 2025
Processing time: 68 Days and 12.8 Hours
Core Tip
Core Tip: Interventional therapy combined with immunotherapy and targeted therapy can significantly prolong the survival of intermediate and advanced hepatocellular carcinoma, but there are very few comparative studies studying the combination of different molecular targeted drugs, different immunotherapeutic drugs, and interventional therapy. Han et al studied the efficacy of lenvatinib or bevacizumab combined with sintilimab and interventional therapy, which can help clarify the efficacy of the combination of different drugs, providing a basis for clinicians to choose the correct treatment strategy for intermediate and advanced hepatocellular carcinoma.